- Record: found
- Abstract: found
- Article: not found
BET bromodomain inhibition of MYC-amplified medulloblastoma.
Pratiti Bandopadhayay
1 ,
Guillaume Bergthold ,
Brian Nguyen ,
Simone Schubert ,
Sharareh Gholamin ,
Yujie Tang ,
Sara Bolin ,
Steven E Schumacher ,
Rhamy Zeid ,
Sabran Masoud ,
Furong Yu ,
Nujsaubnusi Vue ,
William J Gibson ,
Brenton R Paolella ,
Siddhartha S Mitra ,
Samuel H Cheshier ,
Jun Qi ,
Kun-Wei Liu ,
Robert Wechsler-Reya ,
William A Weiss ,
Fredrik J Swartling ,
Mark W Kieran ,
James E Bradner ,
Rameen Beroukhim ,
Yoon-Jae Cho
Feb 15 2014
Read this article at
ScienceOpenPublisherPMC
- open (via free pdf)
- oa repository (via OAI-PMH doi match)
- oa repository (via pmcid lookup)
- oa repository (via page says license)
- oa repository (via page says license)
- oa repository (via page says license)
- oa repository (via page says license)
- oa repository (via page says license)
- oa repository (via page says license)
- oa repository (via page says license)
- oa repository (via page says license)
Powered by 
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
MYC-amplified medulloblastomas are highly lethal tumors. Bromodomain and extraterminal (BET) bromodomain inhibition has recently been shown to suppress MYC-associated transcriptional activity in other cancers. The compound JQ1 inhibits BET bromodomain-containing proteins, including BRD4. Here, we investigate BET bromodomain targeting for the treatment of MYC-amplified medulloblastoma.